BiotechTube
Home/BenevolentAI/Dr. Michael Branney
DM

Dr. Michael Branney

Chief Technology Officer

BenevolentAI

Therapeutic Areas

ImmunologyNeurologyInflammatory Diseases

BenevolentAI Pipeline

DrugIndicationPhase
BEN-2293 / AZD3470Atopic DermatitisPhase 2a
BEN-8744Ulcerative ColitisPhase 1b
Internal ProgramAmyotrophic Lateral Sclerosis (ALS)Preclinical

Leadership Team at BenevolentAI

JS
Joanna Shields, OBE
Chief Executive Officer
DA
Dr. Anne Phelan
Chief Scientific Officer
B(
Baroness (Lola) Young of Hornsey, OBE
Independent Non-Executive Director
View full BenevolentAI profile